Evidence map›Paper›PMID 40878444›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Targeting ROCK2 to Restore Epileptic Synaptic Networks via Mitophagy Activation: Insights from Translational Imaging of SV2A In Vivo.

Ling Xiao, Jing Wang, Bei Chen, Jinhui Yang, Fangyu Wu, Chunyao Zhou, Yifei Zhang, Zhiquan Yang, Dingyang Liu, Lei Tian and 5 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ling XiaoDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.ORCID https://orcid.org/0000-0001-9808-4000
Jing WangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.ORCID https://orcid.org/0009-0008-7299-4936
Bei ChenDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Jinhui YangDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Fangyu WuSchool of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, 311399, China.
Chunyao ZhouNational Clinical Research Center for Geriatric Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Yifei ZhangGE Healthcare, Shanghai, 210000, China.
Zhiquan YangNational Clinical Research Center for Geriatric Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Dingyang LiuNational Clinical Research Center for Geriatric Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Lei TianDivision of Hematology & Oncology, Department of Medicine, School of Medicine, University of California Irvine, Irvine, CA, 92697, USA.
Jianhua YuDivision of Hematology & Oncology, Department of Medicine, School of Medicine, University of California Irvine, Irvine, CA, 92697, USA.
Fei HanDepartment of Pharmacy, College of Biology, Hunan University, Changsha, Hunan, 410082, China.
Yongxiang TangDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.ORCID https://orcid.org/0000-0003-3987-8702
Li FengDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.ORCID https://orcid.org/0000-0001-7658-1399
Shuo HuDepartment of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.ORCID https://orcid.org/0000-0003-0998-8943

Funding

China Postdoctoral Science Foundation 2022M23561China Postdoctoral Science Foundation 2023M733958Clinical Research Foundation of the National Clinical Research Center for Geriatric Diseases 2020LNJJ01Clinical Research Foundation of the National Clinical Research Center for Geriatric Diseases 2023LNJJ16Clinical Research Foundation of the National Clinical Research Center for Geriatric Diseases XIANGYAHunan Provincial Science Fund for Distinguished Young Scholars 2024JJ2094Hunan Provincial Science Fund for Distinguished Young Scholars 2025JJ20076Key Program of Ministry of Industry and Information Technology of China CEIEC-2022-ZM02-0219National Key Clinical Specialty Scientific Research Project Z2023004National Key Program of China 2022YFC2503804National Natural Science Foundation of China 82071461National Natural Science Foundation of China 82271503National Natural Science Foundation of China 82272045National Natural Science Foundation of China 82501746National Natural Science Foundation of China 82571656National Natural Science Foundation of China 82572276National Science Foundation of Hunan Province 2021JJ31060National Science Foundation of Hunan Province 2025JJ60568Science and Technology Innovation Program of Hunan Province 2021RC4056
6 · The paper itself

Abstract

Temporal lobe epilepsy (TLE) is increasingly recognized as a network-level disorder, with contemporary strategies shifting focus from localized epileptic lesions to targeting dysfunctional epileptogenic networks. Leveraging recent advancements in neuroimaging genetics and the growing understanding of brain network remodeling in epilepsy, partial least squares regression is employed to integrate the altered synaptic connectome in TLE patients with a human transcriptomics dataset. The findings reveal a strong association between disruptions in synaptic density similarity networks and the spatial transcriptional profiles of TLE risk genes, identifying Rho-associated protein kinase 2 (ROCK2) as a pivotal gene. In TLE mouse models, treatment with a ROCK2-specific inhibitor mitigates synaptic and neuronal loss, enhances network efficiency within the synaptic density connectome, and significantly reduces seizure frequency. Additionally, transcriptome profiling identifies multiple autophagy-related pathways, and electron microscopy verifies that the administration of the ROCK2 inhibitor restores mitochondrial autophagy and reduces the accumulation of damaged mitochondria. These findings suggest that ROCK2 inhibitors may modulate synaptic networks and mitochondrial dysfunction, offering promising therapeutic potential for the treatment of TLE. This study provides novel insights into the genetic and molecular mechanisms driving epileptic network dysfunction and highlights ROCK2 as a compelling target for translational epilepsy research.

Indexed as

Epilepsy, Temporal LobeMitophagyrho-Associated KinasesSynapsesAnimalsDisease Models, AnimalFemaleHumansMaleMiceMitochondriaTranslational Research, Biomedicalrho-Associated KinasesROCK2 protein, humanRock2 protein, mouse[18F]SynVesT‐1epilepsyimaging transcriptomicsPETROCK2SV2A

Identifiers

PMID40878444
PMCPMC12622553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.